and IC50 < 500 μg/mL on PC-3 cells) [147], by inhibiting the expression of p53, Bcl-2, Her2, VEGF-A and hTERT in human prostate cancer cell lines [146]. This evidence concerns the gene BCL2 and prostate carcinoma.